PET-Based Test Predicts Hormone Therapy Response
By MedImaging International staff writers Posted on 24 Feb 2021 |
Image: Bright spots on PET indicate cancer cells responding to a one-day estrogen challenge (Photo courtesy of Farrokh Dehdashti/ WUSTL)
A positron emission tomography (PET)-based imaging approach can distinguish breast cancer patients unlikely to benefit from hormone therapy (HT), claims a new study.
Researchers at the Washington University (WUSTL; St. Louis, MO, USA) School of Medicine and the University of Illinois at Urbana-Champaign (UIUC; USA) hypothesized that an estradiol challenge would increase progesterone receptor (PgR) levels only in estrogen receptor (ER) positive tumors. To test this hypothesis, they conducted a trial in 43 postmenopausal women with advanced ER+ breast cancer of the uptake of 21-[18F]fluorofuranylnorprogesterone (FFNP, a progestin analog), before and after a one-day estradiol challenge.
The results showed 100% sensitivity and specificity to the estradiol challenge. Post-challenge increase in tumor FFNP uptake was seen in the 28 women with clinical benefit from HT (the responders), but not in the 15 others without clinical benefit (non-responders), indicating that change in tumor FFNP uptake can predict the response to HT in women with ER+ breast cancer. Six-month results also showed significantly longer survival rates in the responding subjects. The study was published on February 2, 2021, in Nature Communications.
“If breast cancer in a patient is estrogen receptor-positive, doctors will usually recommend hormone therapy, even though they know it will only work for slightly more than half the patients,” said senior author Professor Farrokh Dehdashti, MD, of WUSTL. “We observed 100% agreement between the response to estrogen challenge and the response to hormone therapy, even though the participants were on a variety of treatment regimens. This method could provide valuable information to oncologists deciding how best to treat their patients.”
PET is a nuclear medicine imaging technique that produces a 3D image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide tracer, such as FFNP. Tracer concentrations within the body are then constructed in 3D by computer analysis.
Related Links:
Washington University
School of Medicine and the University of Illinois at Urbana-Champaign
Researchers at the Washington University (WUSTL; St. Louis, MO, USA) School of Medicine and the University of Illinois at Urbana-Champaign (UIUC; USA) hypothesized that an estradiol challenge would increase progesterone receptor (PgR) levels only in estrogen receptor (ER) positive tumors. To test this hypothesis, they conducted a trial in 43 postmenopausal women with advanced ER+ breast cancer of the uptake of 21-[18F]fluorofuranylnorprogesterone (FFNP, a progestin analog), before and after a one-day estradiol challenge.
The results showed 100% sensitivity and specificity to the estradiol challenge. Post-challenge increase in tumor FFNP uptake was seen in the 28 women with clinical benefit from HT (the responders), but not in the 15 others without clinical benefit (non-responders), indicating that change in tumor FFNP uptake can predict the response to HT in women with ER+ breast cancer. Six-month results also showed significantly longer survival rates in the responding subjects. The study was published on February 2, 2021, in Nature Communications.
“If breast cancer in a patient is estrogen receptor-positive, doctors will usually recommend hormone therapy, even though they know it will only work for slightly more than half the patients,” said senior author Professor Farrokh Dehdashti, MD, of WUSTL. “We observed 100% agreement between the response to estrogen challenge and the response to hormone therapy, even though the participants were on a variety of treatment regimens. This method could provide valuable information to oncologists deciding how best to treat their patients.”
PET is a nuclear medicine imaging technique that produces a 3D image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide tracer, such as FFNP. Tracer concentrations within the body are then constructed in 3D by computer analysis.
Related Links:
Washington University
School of Medicine and the University of Illinois at Urbana-Champaign
Latest General/Advanced Imaging News
- PET Scans Reveal Hidden Inflammation in Multiple Sclerosis Patients
- Artificial Intelligence Evaluates Cardiovascular Risk from CT Scans
- New AI Method Captures Uncertainty in Medical Images
- CT Coronary Angiography Reduces Need for Invasive Tests to Diagnose Coronary Artery Disease
- Novel Blood Test Could Reduce Need for PET Imaging of Patients with Alzheimer’s
- CT-Based Deep Learning Algorithm Accurately Differentiates Benign From Malignant Vertebral Fractures
- Minimally Invasive Procedure Could Help Patients Avoid Thyroid Surgery
- Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery
- AR Application Turns Medical Scans Into Holograms for Assistance in Surgical Planning
- Imaging Technology Provides Ground-Breaking New Approach for Diagnosing and Treating Bowel Cancer
- CT Coronary Calcium Scoring Predicts Heart Attacks and Strokes
- AI Model Detects 90% of Lymphatic Cancer Cases from PET and CT Images
- Breakthrough Technology Revolutionizes Breast Imaging
- State-Of-The-Art System Enhances Accuracy of Image-Guided Diagnostic and Interventional Procedures
- Catheter-Based Device with New Cardiovascular Imaging Approach Offers Unprecedented View of Dangerous Plaques
- AI Model Draws Maps to Accurately Identify Tumors and Diseases in Medical Images